Dongcheng Pharmaceutical Unit Passes FDA Inspection With Zero 483 Observations

Dongcheng Pharmaceutical (002675) announced on September 11, 2026, that its controlling subsidiary Sino Siam Biotechnique Company Limited underwent an on-site inspection by the US Food and Drug Administration (FDA) from July 17 to July 18, 2026. The company recently received the on-site inspection report issued by the FDA, passing the inspection with No Action Indicated (NAI) and zero Form 483 observations. The inspection covered chondroitin sulfate sodium raw material. This marks the first time Sino Siam Biotechnique's chondroitin sulfate sodium raw material has passed an FDA on-site inspection.